Recent health developments include Eli Lilly's Alzheimer's treatment approval in China, a DOJ lawsuit against CVS for opioid ...

Kathy Ingebrand of Mahtomedi is one of the first people in the country to receive the infusion meant to slow down Alzheimer's disease by up to 35%.

(Corrects paragraph 8 of Dec. 17 story to reflect that the EU regulator reversed its July decision in November to recommend ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

What Eli Lilly (NYSE: LLY) is doing is far more impressive. While many investors may buy it for its growth potential, here's ...

Eli Lilly and EVA Pharma have announced approval from the Egyptian Drug Authority for the human insulin glargine injection.

- USD/JPY: Implied 1-day volatility rises to 21.75 ahead of Fed and BOJ decisions – US financial press [Dec 12th: USD/JPY 1-week implied volatility rises to ~11.7 (BOJ decision is on Dec 19th) – US ...

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Eli Lilly and Co. (LLY) said that the National Medical Products Administration (NMPA) in China has approved Kisunla (donanemab-azbt, ...